News

Roche: RoActemra beats Humira
Enlarge image

BusinessSwitzerland

Roche: RoActemra beats Humira

08.06.2012 - Roche's rheumatoid arthritis treatment RoActemra reduces symptoms more effectively than Abbott Laboratories' Humira when given as a single treatment.

Basel – As the Swiss company reported, a Phase IV trial showed that after 24 weeks of treatment 65% of patients who received RoActemra (tocilizumab) experienced a 20% reduction in swollen and tender joints compared with 49% of those on Humira (adalimumab). „As there are a number of therapies approved for patients with rheumatoid arthritis, it is important for them and their healthcare provider to have the information they need to choose the best individual treatment option,“ said Hal Barron, Chief Medical Officer and Head, Global Product Development. While Roche strongly advocates for its RoActemra, Analysts seem to be less convinced: „Despite these strong efficacy results, it is difficult to assess whether these trial results can be successfully exploited to bring about a change in physicians' prescription habits,“ said Vontobel analyst Andrew Weiss.

„Among a treatment environment of nine different medicines, it is very difficult to make an individual treatment decision for the physician“, acknowledged Karsten Jung, Head of GPS Immunology at Roche, adding that the study aimed at giving comparative data to doctors to help them to decidea in favor of RoActemra when prescribing a treatment.

FDA and EMA have approved RoActemra for use in patients who are either intolerant to or have failed to respond to other medicines to treat inflammation. Roche earned CHF184m in the first quarter 2012 (+46%). Analysts expect peak sales of up to US$2b for the drug. Rheumatoid arthritis and related diseases are one of the most lucrative areas for pharma companies, generating more than US$20b in annual sales. Humira sales are expected to reach US$8.7bn in 2012, according to an EvaluatePharma report.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

MonitoringEU

27.03.2014 In Europe, bacterial resistance to prevalent antimicrobials is common, while multi-resistance remains low, EFSA and ECDC now report.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MORPHOSYS (D)62.00 EUR11.8%
  • BIOINVENT INTERNATIONAL AB (S)2.96 SEK10.9%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%

FLOP

  • CYTOS (CH)0.17 CHF-26.1%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)9.94 USD-9.7%

TOP

  • CO.DON (D)3.30 EUR90.8%
  • BIOTECH PHARMACON (N)17.50 NOK63.6%
  • WILEX (D)0.92 EUR55.9%

FLOP

  • CYTOS (CH)0.17 CHF-94.0%
  • BIONOR PHARMA (N)2.11 NOK-48.0%
  • GW PHARMACEUTICALS (UK)219.25 GBP-39.8%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP791.5%
  • PLETHORA (UK)10.62 GBP585.2%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 17.04.2014